Haeng Kim - Celltrion Pharm Non-Executive Independent Director
| 068760 Stock | KRW 62,400 900.00 1.46% |
Director
Kim Haeng Ok was NonExecutive Independent Director in Celltrion Pharm Inc. since March 22, 2012. Kim worked for three other Koreabased companies including Shinhan Bank. Kim holds a Bachelor degree in Law from Seoul National University, Korea. since 2012.
| Age | 67 |
| Tenure | 12 years |
| Phone | 82 4 3717 7000 |
| Web | https://www.celltrionph.com |
Celltrion Pharm Management Efficiency
The company has return on total asset (ROA) of 0.0341 % which means that it generated a profit of $0.0341 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0891 %, meaning that it generated $0.0891 on every $100 dollars invested by stockholders. Celltrion Pharm's management efficiency ratios could be used to measure how well Celltrion Pharm manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | 0.0891 | |||
| Return On Asset | 0.0341 |
Celltrion Pharm Leadership Team
Elected by the shareholders, the Celltrion Pharm's board of directors comprises two types of representatives: Celltrion Pharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celltrion. The board's role is to monitor Celltrion Pharm's management team and ensure that shareholders' interests are well served. Celltrion Pharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celltrion Pharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jung Seo, Director | ||
| Jungsu Seo, CEO Director | ||
| Haeng Kim, Non-Executive Independent Director | ||
| JongDae Yoo, Managing Director | ||
| EunSuk Choi, Exec | ||
| Jeong Seo, Chief Executive Officer, Director | ||
| Myeong Oh, Senior Vice President | ||
| SangSuk Kim, President | ||
| YunHyun Kang, Managing Director | ||
| Seung Choi, Managing Director | ||
| Yeong Yoo, Vice President | ||
| Jin Wang, Assistant Managing Director | ||
| Gyeong Kim, Non-Executive Independent Director | ||
| Dong Yim, Internal Auditor | ||
| DongHo Woo, Exec | ||
| ChangJin Kim, Managing Director | ||
| Wang Lee, Non-Executive Independent Director | ||
| HyukJin Gwon, Managing Director |
Celltrion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celltrion Pharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0891 | |||
| Return On Asset | 0.0341 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 5.87 T | |||
| Shares Outstanding | 34.05 M | |||
| Shares Owned By Insiders | 57.79 % | |||
| Shares Owned By Institutions | 6.75 % | |||
| Price To Earning | 62.82 X | |||
| Price To Sales | 8.22 X |
Pair Trading with Celltrion Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celltrion Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celltrion Pharm will appreciate offsetting losses from the drop in the long position's value.Moving together with Celltrion Stock
Moving against Celltrion Stock
| 0.84 | 122870 | YG Entertainment | PairCorr |
| 0.79 | 041510 | SM Entertainment | PairCorr |
| 0.74 | 003535 | Hanwha InvestmentSecuri | PairCorr |
| 0.74 | 012330 | Hyundai Mobis | PairCorr |
| 0.65 | 032640 | LG Uplus | PairCorr |
The ability to find closely correlated positions to Celltrion Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celltrion Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celltrion Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celltrion Pharm to buy it.
The correlation of Celltrion Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celltrion Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celltrion Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celltrion Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Celltrion Stock
Celltrion Pharm financial ratios help investors to determine whether Celltrion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celltrion with respect to the benefits of owning Celltrion Pharm security.